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E-mail address: ygyu@kookmin.ac.kr (Y.G. Yu).Human microsomal prostaglandin E synthase-1 (mPGES-1) is an emerging drug target for inﬂammatory
disorders and cancer suppression. Therefore, it is crucially important to discover mPGES-1 inhibitors with
novel structural scaffolds for the development of anti-inﬂammatory drugs. Here, we report the mPGES-1
inhibitors identiﬁed through screening of a chemical library. Initial screening of 1841 compounds out of
200,000 in a master library resulted in 9 primary hits. From the master library, 387 compounds that share
the scaffold structure with the 9 primary hit compounds were selected, of which 3 compounds showed
strong inhibitory activity against mPGES-1 having IC50 values of 1–3 lM. Notably, a derivative of sul-
fonylhydrazide, compound 3b, inhibited the LPS-induced PGE2 production in RAW 264.7 cells. This com-
pound showed novel scaffold structure compared to the known inhibitors of mPGES-1, suggesting that it
could be further developed as a potent mPGES-1 inhibitor.
Crown Copyright  2012 Published by Elsevier Ltd. Open access under CC BY-NC-ND license.Prostaglandin E2 (PGE2) regulates diverse physiological pro-
cesses, including inﬂammation,1–3 reproduction,4 or tumorigene-
sis.5,6 The production of PGE2 in macrophages and other
tissues1,2,7–10 is induced by pro-inﬂammatory stimuli, and an ele-
vated level of PGE2 has been implicated in pain11 and fever.12
Amongst the 3 known human PGE synthases, namely, a cytosolic
prostaglandin E2 synthase (cPGES) and 2 microsomal membrane-
associated prostaglandin E2 synthases referred to as mPGES-1
and mPGES-2—the former is responsible for the pro-inﬂammatory
stimuli-dependent production of PGE2 in various tissues.2,3,6 Re-
cent reports suggest that mPGES-1 is a potential drug target in
chronic inﬂammatory diseases.13 Mice lacking the mPGES-1 gene
showed impaired inﬂammatory and pain responses.14 In addition,
the selective inhibition of mPGES-1 lowered the unwanted side ef-
fects of COX-2 inhibitors which in turn lowered the level of prosta-
glandins downstream of PGH2 such as PGE2, PGI2, thromboxane A,
or PGD2.15 Further, mPGES-1 knockout animals showed viable, fer-
tile, and normal phenotype,14 suggesting that inhibitors of mPGES-
1 could be expected to have anti-inﬂammatory potential without
side effects.
A few inhibitors of mPGES-1 have been developed since they
have the potential application as anti-inﬂammatory therapeuticsevier Ltd.
+82 2 910 4415.
Open access under CC BY-agents. A stable PGH2 analog16, NS-398, which is a COX-2 inhibi-
tor,17 and MK-886, which is a 5-lipoxygenase activating protein
(FLAP) inhibitor,18 were found to inhibit mPGES-1 with IC50 values
of 0.3, 20, and 3.2 lM. Structure-activity relationship (SAR) studies
using MK-886 generated highly potent mPGES-1 inhibitors that
have an indole carboxylic acid structure.19 A virtual screening
method using a structure model of mPGES-1 enabled the identiﬁ-
cation of inhibitory compounds that have structures distinct from
the previously identiﬁed mPGES-1 inhibitors.20 High throughput
screening and optimization of hit compounds resulted in the iden-
tiﬁcation of a phenanthrene imidazole derivative (MF63) or trisub-
stituted urea as highly potent mPGES-1 inhibitors with low IC50
values (1–2 nM) and high bioavailability.21,22
Although the development of novel inhibitors of mPGES-1 has
received great attention, the variety of inhibitors with different
skeletal structures and mPGES-1 structure information are still
limited. Hence, a screening of diverse chemical libraries is required
to provide new mPGES-1 inhibitors with novel scaffolds. Previ-
ously, we reported an optimized expression of recombinant
mPGES-1 in Escherichia coli and a two-enzyme assay method using
15-PGDH.23,24 In order to identify novel mPGES-1 inhibitors, we
screened the compounds deposited in the Korean Chemical Bank
(www.chembank.org). The structural diversity of a master library
of 200,000 compounds was analyzed using the Extended Connec-
tivity Fingerprints 6 (ECFP6), and 1841 compounds representingNC-ND license.
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Scheme 1.
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were selected as a fragment library and tested for their inhibitory
activity against mPGES-1 using a two-enzyme assay method24
(scheme 1). A set of 9 primary hits (compounds 1–9, Fig. 1) showed
more than 80% inhibition of mPGES-1 at 25 lM. Among them,
compound 9 shared a structural motif, namely, the benzothio-
phene group with a previously identiﬁed inhibitor 10 (Fig. 2),
which contained a 5-hydroxyfuran-2(3H)-one extension leading
to a reduced production of PGE2, and the expression of mPGES-1
in a mouse macrophage cell line.25 Rest of the test compounds
showed distinct structural scaffolds compared to the previouslyFigure 1. Structures ofidentiﬁed inhibitors (Fig. 2) such as MF63,21 MK886.2 AF3442,26
YS101,27 a derivative of diarylimidazole (compound 11)28 or licofe-
lone.29 It is worth noting that an amide backbone structure linked
with aromatic ring is a common feature of compound 2, 3, and 5
suggesting that this motif might be important for the inhibitory
activity against mPGES-1.
A number of compounds that shared common scaffolds with the
9 primary hits were selected from the master library. From rigid
docking of the primary hits to the model structure of mPGES-1,
387 compounds that have homologous structure at the binding
pocket were selected from the master library. The inhibitory activ-
ities of these compounds against mPGES-1 were further measured,
and 13 compounds (Fig. 3) that showed about 90% inhibition at
10 lM were identiﬁed. Among them, compounds 1a, 2d, and 3b
showed strong inhibitory activity with IC50 values of 1.4, 0.9 and
1.7 lM, respectively, (Fig. 4). The binding modes of these com-
pounds to mPGES-1 were further examined using molecular dock-
ing. To deﬁne the shape of the mPGES-1 binding site, one of its
inhibitors (compound 11, Fig. 2) was used as the reference com-
pound.28 The output of LigandFit (Fig. 5) showed a reliable correla-
tion between their structures and their inhibitory activities (Fig. 4).
The most active compound 2d (IC50 = 0.9 lM) showed tight bind-
ing to the active site because of many hydrogen bond donors and
hydrogen bond acceptors as compared to the other hits. Remark-
ably, the 2 carbonyl groups in the linker region of compound 2d
form hydrogen bonds with R70, R73, and R126, and the nitroben-
zene moieties form hydrogen bonds with R110, Y28, and G54
(Fig. 5B). Notably, compound 2d also displayed spacious symmetry
with 3b (Fig. 5C), and the carbonyl and the hydroxyl groups inter-
act with R38. Oxygen moiety in the linker region of compound 1a
forms a hydrogen bond with R126 (Fig. 5A). These observations
indicated that the identiﬁed compounds are a good ﬁt in the activethe primary hits.
Figure 2. Structures of the previously reported mPGES-1 inhibitors.
Figure 3. Structures of mPGES-1 inhibitory compounds obtained from screening the derivatives of the primary hits.
S.-J. Park et al. / Bioorg. Med. Chem. Lett. 22 (2012) 7335–7339 7337site pocket of mPGES-1 where MK886 and glutathione are known
to bind.To assess the effects of compound 1a, 2d, and 3b on LPS-
induced PGE2 in RAW 264.7 cells, the production of PGE2 was
Figure 4. Concentration-dependent inhibition of mPGES-1 by compound 1a, 2d, and 3b. The IC50 values of each compound were obtained from the regression of the
inhibition curve and indicated in the graph.
Figure 5. The binding site model of mPGES-1 with compound 1a (A), 2d (B), or 3b (C). Calculations for docking were carried out using LigandFit2 interfaced with Accelrys
Discovery Studio3.1 with a structural model of mPGES-1 (PDB entry; 3DWW). The three-dimensional conformations of the identiﬁed inhibitory compounds were generated
using ‘Generate Conformations’ protocol from the Discovery Studio 3.1.
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Figure 6. Effect of compound 1a, 2d or 3b on LPS-induced PGE2 production in RAW
264.7 cells Cells were treated with only LPS (10 ng/ml) or along with the
compounds (1 or 10 lM) for 24 h. Levels of PGE2 in culture media were quantiﬁed
using EIA kits. NS-398 (3 lM) was used as the positive control. Values shown are
mean ± SD of 3 independent experiments. #p <0.05 versus the control group;
⁄⁄⁄p <0.001 versus the LPS-induced group; signiﬁcant differences between groups
were determined using ANOVA and Dunnett’s post-hoc test. As a positive control
for PGE2 blockage, NS-398 (3 lM), a COX inhibitor,31 was used.
7338 S.-J. Park et al. / Bioorg. Med. Chem. Lett. 22 (2012) 7335–7339measured by EIA30 (Fig. 6). Stimulation of cells with LPS (10 ng/ml)
resulted in a signiﬁcant increase in PGE2 production compared tounstimulated control cells. Pretreatment with compound 3b (1 or
10 lM) markedly inhibited LPS-induced PGE2 production
(59.94 ± 1.44% and 93.3 ± 2.27% at 1 and 10 lM, respectively).
In conclusion, novel mPGES-1 inhibitors have been identiﬁed
from a sequential screening of a fragment library and derivatives
of primary hits selected from the master libraries at Korean Chem-
ical Bank. The identiﬁed inhibitors ﬁt into the GHS-binding site of
mPGES-1, as conﬁrmed from the molecular docking simulation
using a modeled trimeric structure of mPGES-1. Three compounds
(1a, 2d, and 3b) having new structural scaffolds inhibit mPGES-1
with IC50 values in the range of 1–2 lM. One of them namely, com-
pound 3b, also inhibited the LPS-induced PGE2 production in RAW
264.7 cells. Further analysis of the structure-activity relationship of
homologous compounds starting from the newly identiﬁed
mPGES-1 inhibitors and a detailed study of the binding mode are
required for future design of potent inhibitors of mPGES-1.
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